Structure Therapeutics Q1 net loss widens on higher R&D costs

Structure Therapeutics

07/05/2026 22:02

Overview

US biopharma reported Q1 net loss widened yr/yr as R&D and G&A expenses increased

Cash, equivalents and short-term investments totaled $1.5 bln, expected to fund operations through 2028

Outlook

Company expects to initiate aleniglipron Phase 3 trial in Q3 2026

Topline data from ACCESS OLE and Body Composition studies expected in Q3 and Q4 2026

Company projects cash runway through end of 2028

Result Drivers

R&D EXPENSES - Higher Q1 R&D expenses driven by increased clinical trial costs, preclinical research, and more personnel to support GLP-1R franchise advancement

G&A EXPENSES - G&A expenses rose due to expanded infrastructure and higher employee costs to support company growth

Company press release: ID:nGNX8NGlg

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$75.97 mln
Q1 Income From Operations
-$89.38 mln
Q1 Operating Expenses
$89.38 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Structure Therapeutics Inc is $101.00, about 147.3% above its May 6 closing price of $40.84

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)